Search Results for “research” – Page 28 – media

Semaglutide sold for $20.3 billion!

On November 6, Novo Nordisk released its third-quarter report for 2024. In the first nine months of this year, sales increased by 23% to 204.7 billion Danish kroner, of which sales of diabetes and obesity treatment drugs increased by 25% to 191.8 billion Danish kroner. The star product Semaglutide continued to advance by leaps and bounds, with sales of three brands (sugar-lowering injection Ozempic, sugar-lowering tablets Rybelsus, and weight-loss injection Wegovy) reaching 141.213 billion Danish kroner, or about 20.3 billion US dollars, in the first nine months of this year. Not long ago, Eli Lilly also announced its performance, among which the sales of two brands of GIPR/GLP-1R dual agonist Tirzepatide (Mounjaro, a hypoglycemic injection, and Zepbound, a weight loss injection) reached US$11.0284 billion in the first three quarters of this year. Specifically, Mounjaro’s sales revenue was US$8.010 billion, and Zepbound’s sales revenue was US$3.018 billion. Zepbound has been rapidly ...
- Source: drugdu
- 56
- November 9, 2024
New eye medicine company will lay tens of billions of “golden eggs”

In front of the old domestic eye medicine leaders such as Yisheng Bio and Xingqi Eye Medicine, Zhaoke Ophthalmology is a young upstart. In 2021, Zhaoke Ophthalmology successfully landed on the Hong Kong Stock Exchange as the second eye medicine biotechnology company with 25 ophthalmic drug candidates. Three years later, although it has not yet gotten out of the quagmire of losses, Zhaoke Ophthalmology is still working hard in the eye medicine track and finally ushered in the opportunity to overtake on the curve. Two years of rapid growth, fierce attack on the “first billion drug” Recently, Zhaoke Ophthalmology announced that the Phase III clinical trial (China CHAMP) of its eye medicine candidate NVK002 has achieved positive top-line results. NVK002 is an experimental new topical ocular solution for controlling the deepening of myopia in children and adolescents (using 0.01% and 0.02% low-dose atropine). This is the most popular atropine myopia ...
- Source: drugdu
- 68
- November 9, 2024
Global New Drug Progress and New Sharing

Progress in drug research and development 1. Anjin C5aR antagonist “Avamipram” approved for market in China On November 5th, the official website of NMPA announced that the marketing application for avacopan capsules jointly developed by Anjin and CSL Vifor has been approved, presumably for the treatment of anti neutrophil cytoplasmic antibody (ANCA) – related vasculitis (AAV). Afakepan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the allergen C5a, blocking C5a mediated neutrophil activation and migration. The drug was approved by the US FDA in October 2021 for use in combination with standard treatment regimens including glucocorticoids to treat adult active severe ANCA associated vasculitis (MPA and GPA). In July 2024, Anjin reached an agreement with CSL Vifor to acquire commercial rights to Avamipram in Asia and Latin America, including the mainland Chinese market. 2. Pfizer PARP inhibitor “Terazopanib” approved in China On November 5th, ...
- Source: drugdu
- 70
- November 8, 2024
Gan & Lee aims at the hypoglycemic drug market

Collective procurement ‘big winner’ In 1995, Gan Zhongru, who had worked as a postdoctoral fellow and senior biochemist at Merck&Co. in the United States, returned to China to start a business. Three years later, the team formed by Gan Zhongru developed China’s first genetically recombinant human insulin, becoming the third company after Eli Lilly and Novo Nordisk to produce and sell recombinant human insulin. Subsequently, under the leadership of Gan Zhongru and his R&D team, Gan Li Pharmaceutical continued to develop the first long-acting insulin analog, the first fast acting insulin analog, the first pre mixed insulin analog, and the first winter insulin in China. The products covered three insulin functional segments: long-acting, fast acting, and medium acting, becoming the “king of insulin” in China. With the acceleration of domestic insulin substitution in recent years, Ganli Pharmaceutical’s operating revenue has increased from 1.771 billion yuan in 2016 to 3.612 billion ...
- Source: drugdu
- 72
- November 8, 2024
PCR new legend debuts at CIIE! Roche Diagnostics releases LightCycler® PRO

Today, at the 7th China International Import Expo (hereinafter referred to as “CIIE”), Roche Diagnostics China announced that its new molecular detection platform LightCycler® PRO System real-time fluorescence quantitative PCR instrument* (hereinafter referred to as “LightCycler® PRO”) was officially launched in China. Wang Feng, Senior Director of Roche Diagnostics China – Life Sciences Department, Marcus Droege, CEO of TIB Molbiol, James Lee, Global Senior Product Manager of Roche Diagnostics, and other guests attended the LightCycler® PRO launch conference. “As a global leader in in vitro diagnostics, Roche Diagnostics has always empowered scientific research with cutting-edge innovative technologies and led the development of the industry. LightCycler® PRO is another breakthrough innovation in the field of molecular testing. It can achieve 7-channel multiplex testing and has powerful advantages such as accuracy, high efficiency, flexibility, and ease of use. We hope that this time, with the help of the CIIE, it will officially ...
- Source: drugdu
- 54
- November 8, 2024
The world’s first, created in China! Weekly insulin preparation Novozyme® debuts at CIIE, to be launched at the end of the month

On November 6, at the 7th China International Import Expo (hereinafter referred to as “CIIE”), Novo Nordisk held a press conference and announced that the world’s first weekly insulin formulation, Novozymes® (insulin Efficacy Injection), which was exhibited for the first time at this CIIE, will be commercially launched in China at the end of November 2024 for the treatment of type 2 diabetes in adults, ushering in the era of weekly insulin treatment. Professor Peng Yongde, head of the Department of Endocrinology and Metabolism at the First People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, said: “Insulin therapy is still an indispensable and important cornerstone in the diabetes management pathway. As a key component, basal insulin strives to better meet clinical treatment needs to help patients start treatment in a timely manner, improve treatment compliance, increase treatment continuity, and improve patient satisfaction.” Insulin “from day to week” ...
- Source: drugdu
- 56
- November 8, 2024
Cell Drug Conjugates – An Innovative Drug Delivery System

In recent years, cell drug conjugates (CDCs) have gradually become a hot topic in medical research as an emerging drug delivery system. On July 1, 2024, Professor Gu Zhen and others from Zhejiang University published a review paper titled “Cell Drug Conjugates” in the Nature Journal of Biomedical Engineering. The article deeply explores the principles, preparation methods, and applications of this technology in cancer and immune diseases. This article will explain the content of the literature in detail, taking you to understand the core and prospects of this innovative technology. 01 What are cell drug conjugates (CDCs)? Cell drug conjugates are a complex that combines live cells and therapeutic drugs, capable of simultaneously exerting the functions of both, particularly suitable for the treatment of complex diseases such as cancer and autoimmune disorders. Unlike traditional drug delivery systems such as liposomes, nanoparticles, etc., CDCs utilize the physiological characteristics of cells, ...
- Source: drugdu
- 55
- November 7, 2024
Cytokines

Preface B cells are the only cell type capable of differentiating into antibody secreting cells (plasma cells), and they can also present antigens to T cells and produce cytokines. By producing cytokines, B cells affect multiple aspects of immunity: cytokines derived from B cells, including lymphotoxins, are crucial for the individual development, homeostasis, and activation of secondary lymphoid organs, as well as the development of tertiary lymphoid tissue in ectopic sites; Other cytokines derived from B cells, such as interleukin-6 (IL-6), interferon – γ, and tumor necrosis factor, can affect the development of effector cells and memory CD4+T cell responses; Finally, B cells can regulate inflammatory immune responses by secreting IL-10 and IL-35, and “regulatory B cells” are the main source of inhibitory cytokines derived from these B cells in the body. The role of B cells in tissue development and repair Lymphatic organogenesis is mainly regulated by lymphoid tissue ...
- Source: drugdu
- 65
- November 7, 2024
Siemens Healthineers plans to sell some of its shares

Recently, according to Reuters, Ralf Thomas, Chief Financial Officer of Siemens (SIEGn. DE), stated that Siemens may sell some of its shares in Siemens Healthineers (SHLG. DE), Siemens Energy (ENR1n. DE), and Fluence (FLNC. O) to help raise funds for its acquisition of Altair. On October 30th, Siemens signed the final acquisition agreement with AI software leader Altair, with a transaction amount of up to 10.6 billion US dollars (approximately 75 billion yuan), setting a record for the largest merger and acquisition transaction in Siemens Group’s history (excluding the merger of the spin off business Siemens Healthineers). The combination of Altair’s capabilities in simulation, high-performance computing, data science, and artificial intelligence with Siemens Xcelerator (industrial software) will create the world’s most complete portfolio of artificial intelligence design and simulation products, “said Siemens President and CEO Boren 01. Siemens official response Siemens, a century old manufacturing giant originating from Europe, was ...
- Source: drugdu
- 58
- November 7, 2024
CIIE Observation | Eli Lilly’s Two “Focuses”

Today, the seventh CIIE opened grandly in Shanghai. Every year, the CIIE is an excellent opportunity for global pharmaceutical companies to showcase their latest research and development results and expand international markets, and it is also a core window for insight into Chinese market opportunities. This year will be no exception. So, let’s take a look at Eli Lilly, a pharmaceutical company with nearly 150 years of history, and its latest thinking. As an all-around warrior, this year Eli Lilly focused on displaying its latest progress in key global disease areas such as diabetes, obesity, Alzheimer’s disease and anti-tumor. In the big and comprehensive layout, Eli Lilly also revealed its two major focuses of development in China: diabetes and obesity, and Alzheimer’s disease. At this CIIE, Eli Lilly focused on displaying tirpotide. This is not surprising. As Eli Lilly’s flagship product, tirpotide is one of the most competitive GLP-1 drugs ...
- Source: drugdu
- 59
- November 7, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.